William Blair Has Bullish Forecast for Glaukos Q4 Earnings

Glaukos Co. (NYSE:GKOS) – William Blair raised their Q4 2024 EPS estimates for Glaukos in a report issued on Tuesday, November 5th. William Blair analyst M. Andrew now expects that the medical instruments supplier will post earnings per share of ($0.34) for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Glaukos’ current full-year earnings is ($1.98) per share. William Blair also issued estimates for Glaukos’ Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.05) EPS.

A number of other analysts also recently weighed in on GKOS. Morgan Stanley upped their price target on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. JPMorgan Chase & Co. upped their target price on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Needham & Company LLC lifted their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Stifel Nicolaus upped their price objective on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and an average target price of $134.55.

Glaukos Price Performance

Glaukos stock opened at $141.75 on Friday. The firm has a market cap of $7.82 billion, a PE ratio of -46.94 and a beta of 1.02. Glaukos has a one year low of $59.22 and a one year high of $143.58. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.67. The stock’s fifty day moving average price is $129.89 and its two-hundred day moving average price is $120.91.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period last year, the firm earned ($0.50) earnings per share.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $13,216,581.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, COO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $13,216,581.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,525 shares of company stock worth $2,142,029 in the last quarter. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in Glaukos in the third quarter worth approximately $25,000. GAMMA Investing LLC lifted its holdings in Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 486 shares during the period. KBC Group NV raised its stake in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 201 shares during the period. Fifth Third Wealth Advisors LLC bought a new stake in Glaukos in the second quarter worth about $187,000. Finally, Procyon Advisors LLC bought a new stake in shares of Glaukos in the 3rd quarter worth approximately $210,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.